FR20C1016I1 - - Google Patents

Info

Publication number
FR20C1016I1
FR20C1016I1 FR20C1016C FR20C1016I1 FR 20C1016 I1 FR20C1016 I1 FR 20C1016I1 FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 I1 FR20C1016 I1 FR 20C1016I1
Authority
FR
France
Prior art keywords
immunization
vaccines
viral particles
recombinant vsv
vsv viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR20C1016I1 publication Critical patent/FR20C1016I1/fr
Application granted granted Critical
Publication of FR20C1016I2 publication Critical patent/FR20C1016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Recombinant VSV viral particles and the use thereof as vaccines for immunization are described.
FR20C1016C 2002-07-26 2020-05-06 RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS Active FR20C1016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39855202P 2002-07-26 2002-07-26
PCT/CA2003/001125 WO2004011488A2 (en) 2002-07-26 2003-07-28 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

Publications (2)

Publication Number Publication Date
FR20C1016I1 true FR20C1016I1 (en) 2020-06-12
FR20C1016I2 FR20C1016I2 (en) 2022-04-01

Family

ID=31188416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1016C Active FR20C1016I2 (en) 2002-07-26 2020-05-06 RECOMBINANT VACCINES DERIVED FROM VESICULAR STOMATITIS VIRUS AGAINST VIRAL HEMORRHAGIC FEVERS

Country Status (9)

Country Link
US (1) US8012489B2 (en)
EP (1) EP1527087B2 (en)
AT (1) ATE455124T1 (en)
AU (1) AU2003250680A1 (en)
CA (1) CA2493142C (en)
DE (1) DE60330966D1 (en)
ES (1) ES2338416T5 (en)
FR (1) FR20C1016I2 (en)
WO (1) WO2004011488A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709981A1 (en) * 2007-12-18 2009-09-24 Trustees Of Boston University Pre- or post-exposure treatment for filovirus or arenavirus infection
US20110217328A1 (en) * 2007-12-18 2011-09-08 Trustees Of Boston University Compositions and methods for treating ebola virus infection
EP2350270B1 (en) * 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Human ebola virus species and compositions and methods thereof
KR101723900B1 (en) 2009-06-08 2017-04-07 더 유니버시티 오브 웨스트 온타리오 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
US9402891B2 (en) * 2011-06-08 2016-08-02 Ohio State Innovation Foundation Norovirus immunogens and related materials and methods
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
US10179154B2 (en) 2013-11-22 2019-01-15 Yale University Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
US20200181678A1 (en) * 2016-12-15 2020-06-11 Merck Sharp & Dohme Corp. Cell-Based Reporter Assay for Live Virus Vaccines
JP2020534284A (en) * 2017-09-15 2020-11-26 オハイオ ステート イノベーション ファウンデーション How to make and use vaccines and vaccines to prevent respiratory syncytial virus (RSV) infections
US11274282B2 (en) 2019-05-15 2022-03-15 Board Of Regents, The University Of Texas System Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
AU2021256894A1 (en) 2020-04-17 2022-11-03 Regeneron Pharmaceuticals, Inc. Detection assays for coronavirus neutralizing antibodies

Also Published As

Publication number Publication date
EP1527087A2 (en) 2005-05-04
AU2003250680A1 (en) 2004-02-16
ATE455124T1 (en) 2010-01-15
ES2338416T5 (en) 2013-11-20
US20060193872A1 (en) 2006-08-31
AU2003250680A8 (en) 2004-02-16
WO2004011488A3 (en) 2004-04-15
EP1527087B1 (en) 2010-01-13
US8012489B2 (en) 2011-09-06
CA2493142A1 (en) 2004-02-05
WO2004011488A9 (en) 2004-06-03
WO2004011488A2 (en) 2004-02-05
EP1527087B2 (en) 2013-07-17
DE60330966D1 (en) 2010-03-04
ES2338416T3 (en) 2010-05-07
FR20C1016I2 (en) 2022-04-01
CA2493142C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
FR20C1016I1 (en)
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
HK1083454A1 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same 15(il-15)
UA85536C2 (en) Viral antigens
IL212138A0 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
NO964862L (en) papillomavirus vaccines
GB0206359D0 (en) Viral antigens
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PT1673460E (en) Recombinant vaccines and use thereof
PL371007A1 (en) Macrocyclic peptides active against the hepatitis c virus
WO2003103571A3 (en) Flavivirus vaccines
EP1622574A4 (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
IL173929A (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
DE69738512D1 (en) EPSTEIN-BARR VIRUS TYPE B CTL EPITOPES
MXPA03007838A (en) Modified interferon alpha with reduced immunogenicity.
SG185137A1 (en) Biologically active peptides
WO2004041297A3 (en) Modified cytokines for use in cancer therapy
TW200636067A (en) Mutant porcine reproductive and respiratory syndrome virus
AU2003293807A1 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
AU2003217877A1 (en) Eleutherosides as adjuncts for vaccines and immune modulation
AU2003246485A8 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
GB0409559D0 (en) Polypeptide